Nath Bio-Genes (India) Limited (BOM:537291)
India · Delayed Price · Currency is INR 175.55
+4.15 (2.42%)
At close: May 29, 2026
Nath Bio-Genes (India) Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 4,451 | 3,649 | 3,326 | 3,014 | 2,784 |
Other Revenue | - | 1.31 | 1.41 | - | - |
| 4,451 | 3,650 | 3,328 | 3,014 | 2,784 | |
Revenue Growth (YoY) | 21.93% | 9.70% | 10.42% | 8.26% | -9.49% |
Cost of Revenue | 2,015 | 902.49 | 903.04 | 814.33 | 936.65 |
Gross Profit | 2,436 | 2,748 | 2,425 | 2,199 | 1,847 |
Selling, General & Admin | 1,582 | 522.24 | 442.11 | 372.48 | 382.11 |
Other Operating Expenses | 329.34 | 1,716 | 1,482 | 1,338 | 1,088 |
Operating Expenses | 1,951 | 2,276 | 1,957 | 1,741 | 1,501 |
Operating Income | 484.75 | 471.49 | 467.6 | 458.79 | 345.7 |
Interest Expense | -159.58 | -99 | -86.29 | -95.73 | -101.25 |
Interest & Investment Income | - | 35.89 | 3.23 | 0.18 | 10.93 |
Currency Exchange Gain (Loss) | - | 6.4 | -0.14 | 4.3 | 0.59 |
Other Non Operating Income (Expenses) | 77.8 | -4.39 | -3.26 | -5.93 | -3.88 |
EBT Excluding Unusual Items | 402.96 | 410.38 | 381.15 | 361.59 | 252.08 |
Gain (Loss) on Sale of Assets | - | -10.35 | 0.01 | -0.01 | 0.04 |
Other Unusual Items | 60.07 | 5.4 | 34.49 | - | -887.82 |
Pretax Income | 463.04 | 405.84 | 415.65 | 361.64 | -634.34 |
Income Tax Expense | 46.73 | 19.85 | 19.46 | 11.53 | 39.52 |
Net Income | 416.3 | 386 | 396.19 | 350.11 | -673.85 |
Net Income to Common | 416.3 | 386 | 396.19 | 350.11 | -673.85 |
Net Income Growth | 7.85% | -2.57% | 13.16% | - | - |
Shares Outstanding (Basic) | 20 | 19 | 19 | 19 | 19 |
Shares Outstanding (Diluted) | 20 | 19 | 19 | 19 | 19 |
Shares Change (YoY) | 4.41% | - | - | - | - |
EPS (Basic) | 20.98 | 20.31 | 20.85 | 18.42 | -35.46 |
EPS (Diluted) | 20.98 | 20.31 | 20.85 | 18.42 | -35.46 |
EPS Growth | 3.29% | -2.57% | 13.16% | - | - |
Free Cash Flow | -155.78 | 96.61 | 478.18 | 354.85 | -39.56 |
Free Cash Flow Per Share | -7.85 | 5.08 | 25.16 | 18.67 | -2.08 |
Dividend Per Share | 2.000 | 2.000 | 2.000 | 2.000 | 2.000 |
Gross Margin | 54.73% | 75.28% | 72.86% | 72.98% | 66.35% |
Operating Margin | 10.89% | 12.92% | 14.05% | 15.22% | 12.42% |
Profit Margin | 9.35% | 10.57% | 11.91% | 11.62% | -24.21% |
Free Cash Flow Margin | -3.50% | 2.65% | 14.37% | 11.77% | -1.42% |
EBITDA | 524.39 | 509.32 | 500.21 | 488.91 | 376.54 |
EBITDA Margin | 11.78% | 13.95% | 15.03% | 16.22% | 13.53% |
D&A For EBITDA | 39.64 | 37.83 | 32.61 | 30.12 | 30.84 |
EBIT | 484.75 | 471.49 | 467.6 | 458.79 | 345.7 |
EBIT Margin | 10.89% | 12.92% | 14.05% | 15.22% | 12.42% |
Effective Tax Rate | 10.09% | 4.89% | 4.68% | 3.19% | - |
Revenue as Reported | 4,451 | 3,695 | 3,333 | 3,019 | 2,802 |
Advertising Expenses | - | 48.31 | 50.51 | 37.04 | 16.34 |